tiprankstipranks
Regeneron (GB:0R2M)
LSE:0R2M

Regeneron (0R2M) Share Forecast & Price Target

1 Followers
See the Price Targets and Ratings of:

0R2M Analyst Ratings

Strong Buy
22Ratings
18 Buy
3 Hold
1 Sell
Based on 22 analysts giving stock ratings to
Regeneron
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

0R2M Stock 12 Months Forecast

Average Price Target

$1,039.05
▲(7.73% Upside)
Based on 22 Wall Street analysts offering 12 month price targets for Regeneron in the last 3 months. The average price target is $1,039.05 with a high forecast of $1,184.00 and a low forecast of $710.00. The average price target represents a 7.73% change from the last price of $964.45.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"plus_tr_sans","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"696":"$696","1185":"$1,185","818.25":"$818.3","940.5":"$940.5","1062.75":"$1,062.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":1184,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n  <span style=\"color:#199ca5\">$1.18K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1039.05,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n  <span style=\"color:#828080\">$1.04K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":710,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n  <span style=\"color:#912767\">$710.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[696,818.25,940.5,1062.75,1185],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jun<br/>2023","6":"Sep<br/>2023","9":"Dec<br/>2023","12":"Mar<br/>2024","25":"Mar<br/>2025"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,984.92,1000.2338461538461,1015.5476923076923,1030.8615384615384,1046.1753846153847,1061.4892307692307,1076.8030769230768,1092.116923076923,1107.4307692307693,1122.7446153846154,1138.0584615384614,1153.3723076923077,1168.686153846154,{"y":1184,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,984.92,989.0838461538461,993.2476923076923,997.4115384615384,1001.5753846153846,1005.7392307692307,1009.9030769230769,1014.066923076923,1018.2307692307692,1022.3946153846153,1026.5584615384614,1030.7223076923076,1034.8861538461538,{"y":1039.05,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,984.92,963.7723076923077,942.6246153846154,921.4769230769231,900.3292307692308,879.1815384615385,858.0338461538462,836.8861538461538,815.7384615384615,794.5907692307692,773.4430769230769,752.2953846153846,731.1476923076923,{"y":710,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":819.03,"date":1679616000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":825.867,"date":1680825600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":760.166,"date":1683244800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":734.71,"date":1685664000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":697.42,"date":1688688000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":775.329,"date":1691107200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":835.515,"date":1693526400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":839.05,"date":1696550400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":818.4,"date":1698969600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":812.87,"date":1701388800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":917.442,"date":1704412800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":944.55,"date":1706832000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":984.92,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$1,184Average Price Target$1,039Lowest Price Target$710.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Barclays
$1050.00
Buy
8.87%
Upside
Assigned
02/14/24
Analysts Offer Insights on Healthcare Companies: Health Catalyst (NASDAQ: HCAT), Regeneron (NASDAQ: REGN) and Merck & Company (NYSE: MRK)
DZ BANK AG
$1068.00
Buy
10.74%
Upside
Reiterated
02/07/24
Regeneron Pharma (REGN) PT Raised to $1,068 at DZ BankDZ Bank analyst Elmar Kraus raised the price target on Regeneron Pharma (NASDAQ: REGN) to $1,068.00 (from $915.00) while maintaining a Buy rating.
Oppenheimer
$1125.00
Buy
16.65%
Upside
Reiterated
02/06/24
Analysts' Top Healthcare Picks: Intuitive Surgical (ISRG), Vertex Pharmaceuticals (VRTX)
UBS
$1090.00
Buy
13.02%
Upside
Reiterated
02/06/24
Regeneron Pharma (REGN) PT Lowered to $1,090 at UBSUBS analyst Colin Bristow lowered the price target on Regeneron Pharma (NASDAQ: REGN) to $1,090.00 (from $1,112.00) while maintaining a Buy rating.
Canaccord Genuity
$1152.00
Buy
19.45%
Upside
Reiterated
02/05/24
Regeneron price target raised to $1,152 from $1,066 at CanaccordRegeneron price target raised to $1,152 from $1,066 at Canaccord

Best Analysts Covering Regeneron

Which Analyst Should I Follow If I Want to Buy GB:0R2M and Sell After:
1 Month
Hartaj SinghOppenheimer
Success Rate
21/33 ratings generated profit
64%
Average Return
+3.32%
reiterated a buy rating 2 months ago
Copying Hartaj Singh's trades and holding each position for 1 Month would result in 63.64% of your transactions generating a profit, with an average return of +3.32% per trade.
dummydummy
Success Rate
0/0 ratings generated profit
0%
Average Return
0.00%
a rating ―
Copying dummy's trades and holding each position for XXXX would result in 0.10% of your transactions generating a profit, with an average return of 0.00% per trade.
Premium Content
Find out which analyst has the highest Average Return & Success Rate
Go Premium
3 Months
Mohit BansalWells Fargo
Success Rate
13/19 ratings generated profit
68%
Average Return
+5.99%
assigned a buy rating 3 days ago
Copying Mohit Bansal's trades and holding each position for 3 Months would result in 68.42% of your transactions generating a profit, with an average return of +5.99% per trade.
dummydummy
Success Rate
0/0 ratings generated profit
0%
Average Return
0.00%
a rating ―
Copying dummy's trades and holding each position for XXXX would result in 0.10% of your transactions generating a profit, with an average return of 0.00% per trade.
Premium Content
Find out which analyst has the highest Average Return & Success Rate
Go Premium
1 Year
Mohit BansalWells Fargo
Success Rate
18/19 ratings generated profit
95%
Average Return
+18.91%
assigned a buy rating 3 days ago
Copying Mohit Bansal's trades and holding each position for 1 Year would result in 94.74% of your transactions generating a profit, with an average return of +18.91% per trade.
2 Years
Hartaj SinghOppenheimer
Success Rate
32/33 ratings generated profit
97%
Average Return
+46.48%
reiterated a buy rating 2 months ago
Copying Hartaj Singh's trades and holding each position for 2 Years would result in 96.97% of your transactions generating a profit, with an average return of +46.48% per trade.
dummydummy
Success Rate
0/0 ratings generated profit
0%
Average Return
0.00%
a rating ―
Copying dummy's trades and holding each position for XXXX would result in 0.10% of your transactions generating a profit, with an average return of 0.00% per trade.
Premium Content
Find out which analyst has the highest Average Return & Success Rate
Go Premium
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

0R2M Analyst Recommendation Trends

Rating
Nov 23
Dec 23
Jan 24
Feb 24
Mar 24
Strong Buy
0
0
0
0
0
Buy
28
42
51
52
44
Hold
7
7
7
5
5
Sell
3
3
4
3
3
Strong Sell
0
0
0
0
0
total
38
52
62
60
52
In the current month, 0R2M has received 44 Buy Ratings, 5 Hold Ratings, and 3 Sell Ratings. 0R2M average Analyst price target in the past 3 months is $1,039.05.
Each month's total comprises the sum of three months' worth of ratings.
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

0R2M Financial Forecast

0R2M Earnings Forecast

Next quarter’s earnings estimate for 0R2M is $10.04 with a range of $8.41 to $12.34. The previous quarter’s EPS was $11.86. 0R2M beat its EPS estimate 100.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 33.96% of the time in the same period. In the last calendar year 0R2M has Outperformed its overall industry.
Next quarter’s earnings estimate for 0R2M is $10.04 with a range of $8.41 to $12.34. The previous quarter’s EPS was $11.86. 0R2M beat its EPS estimate 100.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 33.96% of the time in the same period. In the last calendar year 0R2M has Outperformed its overall industry.

0R2M Sales Forecast

Next quarter’s sales forecast for 0R2M is $3.22B with a range of $3.00B to $3.51B. The previous quarter’s sales results were $3.43B. 0R2M beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 46.34% of the time in the same period. In the last calendar year 0R2M has Outperformed its overall industry.
Next quarter’s sales forecast for 0R2M is $3.22B with a range of $3.00B to $3.51B. The previous quarter’s sales results were $3.43B. 0R2M beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 46.34% of the time in the same period. In the last calendar year 0R2M has Outperformed its overall industry.

0R2M Stock Forecast FAQ

What is GB:0R2M’s average 12-month price target, according to analysts?
Based on analyst ratings, Regeneron’s 12-month average price target is $1,039.05.
    What is GB:0R2M’s upside potential, based on the analysts’ average price target?
    Regeneron has 7.73% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Regeneron a Buy, Sell or Hold?
          Regeneron has a conensus rating of Strong Buy, which is based on 18 buy ratings, 3 hold ratings and 1 sell ratings.
            What is Regeneron’s share price target?
            The average share price target for Regeneron is $1,039.05. This is based on 22 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is $1,184.00 ,and the lowest forecast is $710.00. The average share price target represents 7.73% Increase from the current price of $964.45.
              What do analysts say about Regeneron?
              Regeneron’s analyst rating consensus is a Strong Buy. This is based on the ratings of 22 Wall Streets Analysts.
                How can I buy shares of Regeneron?
                To buy shares of GB:0R2M, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.
                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis